Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ann Falsey, MD
University of Rochester
Principal Investigator - Magda Sobieszczyk, MD
Columbia University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
84 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Quillota, Chile
- Research Site
Santiago, Chile
- Research Site
Santiago, Chile
- Research Site
Callao, Peru
- Research Site
Lima, Peru
- Research Site
Lima Cercado, Peru
- Research Site
Phoenix, Arizona, United States
- Research Site
Scottsdale, Arizona, United States
- Research Site
Little Rock, Arkansas, United States
- Research Site
Berkeley, California, United States
- Research Site
El Centro, California, United States
- Research Site
Los Angeles, California, United States
- Research Site
Los Angeles, California, United States
- Research Site
San Diego, California, United States
- Research Site
San Diego, California, United States
- Research Site
San Francisco, California, United States
- Research Site
San Francisco, California, United States
- Research Site
Torrance, California, United States
- Research Site
Denver, Colorado, United States
- Research Site
Danbury, Connecticut, United States
- Research Site
Coral Gables, Florida, United States
- Research Site
Lake Worth, Florida, United States
- Research Site
Miami Lakes, Florida, United States
- Research Site
Orlando, Florida, United States
- Research Site
Honolulu, Hawaii, United States
- Research Site
Meridian, Idaho, United States
- Research Site
Chicago, Illinois, United States
- Research Site
Indianapolis, Indiana, United States
- Research Site
Ankeny, Iowa, United States
- Research Site
Fairway, Kansas, United States
- Research Site
Kansas City, Kansas, United States
- Research Site
Wichita, Kansas, United States
- Research Site
Wichita, Kansas, United States
- Research Site
Lexington, Kentucky, United States
- Research Site
Lake Charles, Louisiana, United States
- Research Site
Monroe, Louisiana, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Baltimore, Maryland, United States
- Research Site
Bethesda, Maryland, United States
- Research Site
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Aug 2020
- Primary completion
- 5 Mar 2021
- Completion
- 10 Feb 2023
- Last update posted
- 5 Feb 2024
- Registered enrollment
- 32,450
- Registry id
- NCT04516746
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.